Goal guide
Peptides for Visceral Fat: What the Evidence Actually Shows
Visceral fat is the fat around the organs, and it is measured by CT or MRI rather than by a scale. One peptide is approved specifically to reduce it — tesamorelin, for excess abdominal fat in HIV-associated lipodystrophy — and its trials were run entirely in that population. The GLP-1 and GIP drugs reduce it too, as a consequence of reducing everything. The registry footprint for the two peptides most often sold for belly fat is thin: in August 2026, one terminated 2006 study for CJC-1295, and nothing at all for AOD-9604.
6
3
3
2
Ranked by evidence
What actually has evidence behind it
Ordered by how far the published human evidence goes — strongest first. Availability is a separate question from evidence, so it is labeled separately.
Tesamorelin (Egrifta)
FDA-approvedRandomized trialsEvidence strength: Randomized trials. Randomized controlled trials in humans, at scale.
What it is
A growth-hormone-releasing factor analog, approved for one indication: reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy.
What the evidence shows
The pivotal trial randomized adults with HIV and excess abdominal fat to tesamorelin or placebo and reported a reduction in visceral adipose tissue as measured by CT. A pooled analysis of two multicentre, double-blind, placebo-controlled phase 3 trials with safety-extension data confirmed the effect on visceral fat in that population. A later randomized, double-blind, multicentre trial in people with HIV and non-alcoholic fatty liver disease found tesamorelin reduced liver fat as well.1,2,4
The catch
All three of those trials were run in people with HIV, and HIV-associated lipodystrophy is the population the approval covers. It moves visceral fat rather than the number on the scale, and the effect depends on continued treatment. If you do not have that condition, none of these numbers were measured in anyone like you.
Approved for this use and available by prescription.
Tirzepatide (Zepbound, Mounjaro)
FDA-approvedRandomized trialsEvidence strength: Randomized trials. Randomized controlled trials in humans, at scale.
What it is
A weekly GIP and GLP-1 receptor agonist. Its visceral-fat evidence comes from imaging substudies rather than from a trial designed around visceral fat.
What the evidence shows
The SURPASS-3 MRI substudy scanned 296 adults with type 2 diabetes and a high fatty liver index at week 52. From a mean baseline liver fat content of 15.71%, the pooled tirzepatide 10 mg and 15 mg groups fell 8.09 percentage points against 3.38 on daily titrated insulin degludec — a treatment difference of 4.71 points. The same substudy reported significant reductions in visceral adipose tissue and abdominal subcutaneous adipose tissue volumes against insulin degludec, and the fall in liver fat correlated with the fall in visceral fat.6
The catch
This was a substudy in people with type 2 diabetes and a fatty liver, against an insulin comparator rather than placebo, with liver fat as the primary endpoint. Visceral fat was a secondary reading. It shows the compartment moves; it was not designed to quantify how much it moves in someone without diabetes.
Approved for this use and available by prescription.
Semaglutide (Wegovy, Ozempic)
FDA-approvedRandomized trialsEvidence strength: Randomized trials. Randomized controlled trials in humans, at scale.
What it is
A weekly GLP-1 receptor agonist. Its visceral-fat data likewise comes from a subset of a weight-loss trial, not from a visceral-fat trial.
What the evidence shows
A post hoc analysis of the 68-week STEP 6 trial examined the 180 Japanese participants who had visceral fat area measured — 89 on semaglutide 2.4 mg, 46 on 1.7 mg and 45 on placebo, with a mean baseline visceral fat area of 170.0 cm². Both semaglutide doses reduced visceral fat area against placebo across every subgroup examined. Baseline visceral fat area correlated with body weight (r = 0.415), BMI (r = 0.374) and waist circumference (r = 0.458 and r = 0.555 by two criteria).5
The catch
A post hoc analysis of 180 people in one country is a supporting finding, not a primary result, and post hoc means the question was asked after the data existed. It also does not tell you whether visceral fat fell faster than fat everywhere else — reducing everything reduces this too.
Approved for this use and available by prescription.
Sermorelin and other GHRH peptides
Compounding restrictedEarly humanEvidence strength: Early human. Small, open-label, or phase 1/2 trials. Promising, unproven.
What it is
Shorter growth-hormone-releasing hormone analogs, sold on the same mechanism that tesamorelin uses — raise growth hormone, and visceral fat falls.
What the evidence shows
A 2015 review of human GHRH studies drew on data from HIV-infected individuals and from individuals with general obesity, and reported that GHRH treatment significantly reduces visceral fat, improves dyslipidemia and reduces markers of cardiovascular risk — while calling for further research on long-term efficacy and safety. A 2026 orthopaedic review groups sermorelin with tesamorelin, CJC-1295 and ipamorelin as secretagogues acting through IGF-1 signalling, and states that clinical trials are currently lacking across the compounds it covers.3,7
The catch
The class effect being real is not the same as a given product having been tested. As of August 2026, a ClinicalTrials.gov intervention search for sermorelin returns 27 studies; the ones listing abdominal obesity are a withdrawn study with zero participants enrolled, a completed 60-participant phase 2 in abdominal obesity with growth hormone deficiency, and two tesamorelin studies. Peptide compounding is separately under active FDA restriction.
Under active FDA restriction — compliant pharmacies decline to sell it.
CJC-1295
Compounding restrictedAnimal onlyEvidence strength: Animal only. Rodent or cell studies. Nothing published in humans.
What it is
A long-acting growth-hormone-releasing hormone analog, usually sold blended with ipamorelin and marketed for abdominal fat.
What the evidence shows
A 2026 orthopaedic review lists it among growth-hormone secretagogues that activate IGF-1 signalling, alongside a stated lack of clinical trials. A 2026 sports medicine review reports the same pattern across the unapproved peptides it examined: favourable animal results, scarce rigorous human data.7,8
The catch
It was tested for exactly this goal, once. As of August 2026, a ClinicalTrials.gov intervention search for CJC-1295 returns a single record: a 120-participant phase 2 in HIV patients with visceral obesity, started in December 2005 and terminated in September 2006, with no results posted. Twenty years later that is still the whole registry footprint.
Under active FDA restriction — compliant pharmacies decline to sell it.
AOD-9604
Research use onlyAnecdotalEvidence strength: Anecdotal. User reports and forum consensus. No controlled data.
What it is
A fragment of human growth hormone marketed as a fat-loss peptide, with abdominal fat the usual claim.
What the evidence shows
It appears in the 2026 orthopaedic peptide review inside the growth-hormone-secretagogue group and in the 2026 sports medicine review of unapproved peptides sold direct to patients. The supporting work described in both is preclinical.7,8
The catch
As of August 2026, a ClinicalTrials.gov intervention search for AOD-9604 returns zero studies. There is no registered trial measuring visceral fat, or any other outcome, for this compound in people.
Sold for laboratory use. Not a legal medicine for people.
What visceral fat is, and why the measurement matters
Visceral fat sits around the organs rather than under the skin, and it tracks with metabolic risk more closely than total weight does. It is measured by CT or MRI cross-section, or by DXA-derived estimates — not by a tape measure and not by a scale.
That distinction runs through this whole page. A trial that reported weight loss has not reported visceral fat loss, and the reverse is also true: tesamorelin reduces visceral adipose tissue without being a weight-loss drug 1.
The one approval, and how narrow it is
Tesamorelin is approved for reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Its pivotal trial and the pooled phase 3 analysis were both run in that population 2. A later trial in people with HIV and fatty liver found it reduced liver fat too 4.
The class effect is not confined to that condition — a 2015 review reported that GHRH treatment reduces visceral fat in people with general obesity as well as in people with HIV 3. What remains true is that tesamorelin's own approval, and its own trials, cover the narrower group. "The class works" and "this product was tested in people like you" are different statements, and this site does not merge them.
The GLP-1 route
If your reason for caring about visceral fat is metabolic risk, the drugs with the largest evidence base reduce it as part of reducing everything. Tirzepatide cut liver fat by 8.09 percentage points and reduced visceral and subcutaneous abdominal fat volumes in the SURPASS-3 MRI substudy 6. Semaglutide reduced visceral fat area against placebo in every subgroup of a STEP 6 post hoc analysis 5.
Both are secondary or post hoc readings from trials built around other endpoints. They are consistent, and they are not the same as a trial designed to answer this question.
What the belly-fat peptides have behind them
One terminated phase 2 from 2006, and nothing else. That is the registry position for CJC-1295 as of August 2026, and a search for AOD-9604 returns nothing at all. The mechanism story these are sold on is borrowed from tesamorelin, which was tested; they were not. Our weight-loss page covers the same borrowed-mechanism problem for total body weight.
Questions
Frequently asked questions
Which peptide reduces visceral fat?
Tesamorelin is the one approved specifically for it, and its approval covers excess visceral abdominal fat in adults with HIV-associated lipodystrophy — the population its pivotal trial and pooled phase 3 analysis enrolled. Tirzepatide and semaglutide also reduce visceral fat in imaging substudies, as part of reducing overall fat.
Can I use tesamorelin if I do not have HIV?
The published trials were conducted in people with HIV-associated lipodystrophy, so nothing in them was measured in anyone outside that group. A 2015 review reported that GHRH treatment reduces visceral fat in people with general obesity as well as in people with HIV, but that is a statement about the class, not about tesamorelin's own tested population. This is a prescriber's decision, and nothing here is a dose or a recommendation.
Does CJC-1295 reduce belly fat?
As of August 2026, a ClinicalTrials.gov intervention search for CJC-1295 returns one study: a 120-participant phase 2 in HIV patients with visceral obesity, started in December 2005 and terminated in September 2006, with no results posted. Two 2026 reviews describe clinical evidence for this class of secretagogue as lacking.
How is visceral fat actually measured?
By cross-sectional imaging — CT or MRI — or by DXA-derived estimates. The trials on this page used CT for tesamorelin, MRI for the tirzepatide substudy, and a visceral fat area measurement for the semaglutide post hoc analysis. Waist circumference correlates with it (r = 0.458 and r = 0.555 in the STEP 6 analysis) but is not the same measurement.
Keep reading
Go deeper on one compound
Tesamorelin
Full trial-by-trial evidence review.
Tirzepatide
Full trial-by-trial evidence review.
Semaglutide
Full trial-by-trial evidence review.
Retatrutide vs. Tirzepatide: What the Trials Actually Found
Two trial programs, compared side by side — not head to head.
Reconstitution calculator
Converts a dose you've chosen into syringe units. Recommends nothing.
Sources
References
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Falutz J, Mamputu JC, Potvin D, et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Stanley TL, Grinspoon SK (2015). Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Hormone & IGF Research. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. https://pubmed.ncbi.nlm.nih.gov/31611038/
- Kadowaki T, Nishida T, Ogawa W, et al. (2025). Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial. Obesity Research & Clinical Practice. https://pubmed.ncbi.nlm.nih.gov/40189961/
- Gastaldelli A, Cusi K, Fernández Landó L, et al. (2022). Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes & Endocrinology. https://pubmed.ncbi.nlm.nih.gov/35468325/
- Rahman OF, Lee SJ, Seeds WA (2026). Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Global Research & Reviews. https://pubmed.ncbi.nlm.nih.gov/41490200/
- Mendias CL, Awan TM (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. https://pubmed.ncbi.nlm.nih.gov/41966639/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.